SCHEMBL7670593

SCHEMBL7670593

Cc1ccc(C(=O)Nc2ccc(S(=O)(=O)N[C@H](C)C(=O)OC(C)(C)C)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.55
MMP9 P14780 4/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
ALDH1A1 P00352 2/20 0.52
HPGD P15428 2/20 0.52
XBP1 P17861 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
MMP2 P08253 3/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
MAPT P10636 2/20 0.48
HSD17B10 Q99714 2/20 0.48
PLAU P00749 2/20 0.48
HPN P05981 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7669662 0.90 MMP9 (0.62) LMNAMMP9MEN1KMT2AALDH1A1
SCHEMBL7671437 0.89 MMP9 (0.59) LMNAMMP9MEN1KMT2AALDH1A1
SCHEMBL7667739 0.89 MMP9 (0.59) LMNAMMP9MEN1KMT2AALDH1A1
SCHEMBL7674329 0.86 PLAU (0.59) LMNAMMP9MEN1KMT2AALDH1A1
SCHEMBL7673449 0.86 PLAU (0.59) LMNAMMP9MEN1KMT2AALDH1A1
SCHEMBL7668955 0.85 PLG (0.48) LMNAMEN1KMT2AALDH1A1HPGD
SCHEMBL7675164 0.84 MMP9 (0.52) LMNAMMP9MEN1KMT2AALDH1A1
SCHEMBL7667625 0.84 MMP9 (0.57) LMNAMMP9MEN1KMT2AALDH1A1
SCHEMBL7674729 0.83 MMP9 (0.66) LMNAMMP9MEN1KMT2AALDH1A1
SCHEMBL7673629 0.81 MMP9 (0.76) MMP9ALDH1A1TDP1MMP2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6403644-B1 FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-11 US disclosed
US-6177466-B1 Sulfonylamino acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-23 US disclosed
EP-0757037-A2 Sulfonylamino acid derivatives as metalloproteinase inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1997-02-05 EP disclosed